Immunotherapy for the Treatment of Cancer

Targeting multiple myeloma, triple-negative breast cancer, non-Hodgkin's lymphoma and more with highly potent biopharmaceutical drugs designed for targeted therapy.

View Product Pipeline


GT Biopharma, Inc. a targeted immunotherapies company with close to market treatments for Central Nervous System diseases.


Latest News

GT Biopharma, Inc. Starts FDA Phase 1 Clinical Trial for Myasthenia Gravis Autoimmune Muscular Disease
Dec 6, 2017 • 8:00 EST | Read More

Dr. Jeffrey Miller to Present Data on GT Biopharma Next Generation TriKE (OXS-C3550) at the Upcoming ASH Meeting in Atlanta, Ga
Nov 30, 2017 • 8:00 EST | Read More


GT Biopharma, Inc. OTCQB: GTBP
Loading... Change
Loading... Volume
Loading... 52 Week Range